The risk of cardiovascular adverse effects associated with JAK inhibitors in rheumatoid arthritis: a protocol for a systematic review and meta-analysis

Study identification

• EU PAS number:
  EUPAS35534
• Study ID:
  43016
• Official title and acronym:
  The risk of cardiovascular adverse effects associated with JAK inhibitors in rheumatoid arthritis: a protocol for a systematic review and meta-analysis
• DARWIN EU® study:
  No
• Study countries:
  Portugal
• Study status:
  Finalised

Research institutions and networks

Institutions

Pharmacovigilance and Pharmacoepidemiology, AIBILI

Portugal

Study timelines

Date when funding contract was signed

Planned: 01/04/2020

Actual: 01/04/2020

Study start date

Planned: 01/04/2020

Actual: 01/04/2020

Date of final study report

Planned: 31/12/2020

Actual: 31/12/2020

Sources of funding

Other

More details on funding

AIBILI

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable